Back to search

Article

BRCA2 reversion mutation-independent resistance to PARP inhibition in prostate cancer through loss of function perturbations in the DNA pre-replication complex

2025-04-24

Abstract excerpt

Recent approvals of PARP inhibitors (PARPi) for BRCA-mutant metastatic castration resistant prostate cancer (mCRPC) necessitate an understanding of the factors that shape sensitivity and resistance. Reversion mutations that restore homologous recombination (HR) repair are detected in ∼50-80% of BRCA-mutant patients who respond but subsequently relapse, but there is currently little insight into why only ∼50% of BR...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
141a1ea8-e8b6-5d1e-baec-c1d265f54d4d
DOI
10.1101/2025.04.20.649668
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
BRCA2 reversion mutation-independent resistance to PARP inhibition in prostate cancer through loss of function perturbations in the DNA pre-replication complexDOI 10.1101/2025.04.20.649668
BRCA2 reversion mutation-independent resistance to PARP inhibition through impaired DNA prereplication complex function.Semantic proximity
Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression.Semantic proximity
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancerSemantic proximity
Drug-gene interaction screens coupled to tumour data analyses identify the most clinically-relevant cancer vulnerabilities driving sensitivity to PARP inhibitionSemantic proximity
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancerSemantic proximity
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer.Semantic proximity
Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapySemantic proximity
Emergence of BRCA Reversion Mutations in Prostate Cancer Prior to PARP Inhibitor Exposure: Clinical and Therapeutic Implications.Semantic proximity
Targeting MALAT1 Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in Prostate CancerSemantic proximity
Targeting MALAT1 Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in Prostate CancerSemantic proximity
Drug–gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP InhibitionSemantic proximity
A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivitiesSemantic proximity
Select a neighboring publication to make it the new centre.